vimarsana.com

Page 5 - அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Results from IMBRUVICA® RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia

ABBVie , today announced extended long-term data from the Phase 3 RESONATE-2 study evaluating single-agent IMBRUVICA versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemiasmall lymphocytic lymphoma . 1 These data will be presented on June 4 th during the 2021 American Society of Clinical Oncology Annual Meeting . Additionally, new data will be presented during the .

Merck & Company, Inc (NYSE:MRK), Astrazeneca PLC (NYSE:AZN) - AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.